ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CLDX vs ORKA // FREE CASH FLOW YIELD

Celldex Therapeutics Inc. (NASDAQ) VS. Oruka Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CLDX 0 — ORKA 9
▲ FREE CASH FLOW YIELD LEADER: ORKA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDX VS. ORKA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CLDX ORKA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -18.80% -16.20 ORKA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -9.10% -1.38% -7.72 ORKA /fcf-yield <GO>
Operating Margin -60.00% -6.80% -53.20 ORKA /operating-margins <GO>
Net Profit Margin -60.00% -5.90% -54.10 ORKA /net-margins <GO>
Revenue Growth (YoY) -65.00% -4.40% -60.60 ORKA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 20.25 26.00 -5.75 ORKA /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 ORKA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.7 67.0 -21.30 ORKA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.13 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 28.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.36B $6.41B -$4.05B ORKA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CLDX REV ORKA REV CLDX GROSS % ORKA GROSS % CLDX FCF ORKA FCF
FY 2025 $1.5M $341.7M 87.1% — -$213.7M -$88.4M
FY 2024 $7.0M $246.7M 97.2% — -$159.7M -$58.0M
FY 2023 $6.9M $20.4M — — -$107.3M -$5.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDX // BETA —
ORKA // BETA 1.13